Refine
Has Fulltext
- yes (24) (remove)
Is part of the Bibliography
- yes (24)
Year of publication
Document Type
- Journal article (24) (remove)
Language
- English (24) (remove)
Keywords
- adrenocortical carcinoma (4)
- biomarker (3)
- hypercortisolism (3)
- miRNA (3)
- ACTH (2)
- CYP2W1 (2)
- Cushing’s disease (2)
- FGF-pathway (2)
- FGFR (2)
- SOAT1 (2)
Institute
- Medizinische Klinik und Poliklinik I (24)
- Pathologisches Institut (10)
- Comprehensive Cancer Center Mainfranken (4)
- Institut für Pharmakologie und Toxikologie (2)
- Urologische Klinik und Poliklinik (2)
- Center for Computational and Theoretical Biology (1)
- Institut für Klinische Biochemie und Pathobiochemie (1)
- Institut für Rechtsmedizin (1)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (1)
- Klinik und Poliklinik für Anästhesiologie (ab 2004) (1)
We have previously identified serum miR-483-5p as a preoperative diagnosis and prognosis biomarker for adrenocortical cancer (ACC). Here, we aimed to determine whether circulating miR-483-5p levels measured 3 months post-operatively distinguished patients with good prognosis (no recurrence for at least 3 years; NR3yrs) from patients with poor prognosis (recurrence or death within 3 years after surgery; R < 3yrs). We conducted a single-center retrospective analysis using sera from 48 patients with ACC that were initially non-metastatic and treated by surgery. Sera sampled within 3 months after surgery were available in 26 patients. MiR-483-5p absolute circulating levels were measured using quantitative PCR. Thirteen patients showed a recurrence before 3 years (=R < 3yrs). Thirteen patients showed no recurrence within 3 years, including 11 patients with a follow-up longer than 3 years (=NR3yrs). Serum miR-483-5p levels were higher in R < 3yrs than in NR3yrs: 1,541,990 ± 428,377 copies/mL vs. 388,457 ± 62,169 copies/mL (p = 0.002). Receiver operating characteristic analysis showed that a value of 752,898 copies/mL distinguished R < 3yrs from NR3yrs with 61.5% sensitivity (CI 31.6–86.1) and 100% specificity (CI 71.5–100) with an area under the curve of 0.853. Patients with a value below this threshold had a significantly longer recurrence-free and overall survival. In multivariate analysis, miR-483-5p provided the single best prognostic value for recurrence-free survival (RFS) (hazard ratio (HR) for recurrence 5.98, p < 0.011) but not for overall survival. Our study suggests that serum miR-483-5p is a potent early post-operative biomarker for ACC prognosis that might be a better predictor of RFS than currently used markers.